ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
Status:
Not yet recruiting
Trial end date:
2025-02-28
Target enrollment:
Participant gender:
Summary
Open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the
safety/tolerability and determine the recommended Phase II Dose (RP2D) of ET140203 T-cells in
pediatric subjects who are AFP-positive/HLA-A2-positive and have relapsed/refractory HB,
HCN-NOS, or HCC.